Humanigen Inc (HGENQ)

[Corundum]

Two problems going after vented patients. First, vented patients are often too far gone for much of anything to help. It will be difficult to prove in a study (CYDY results so far are not much more than random, unless they "fix" the study). However, they may still be able to show some benefit, and if they do, more power to them. They do have some much bigger competition investigating that end of the market. Second, vaccines and Lenz will be reducing the number of people on vents, so their market market is about to shrink to a miniscule amount by the time they ever get an approval.

In addition, CYDY will find it difficult to get an EUA without much more invested in proving out their manufacturing capability, quality control, statistical accuracy, etc, etc. They are not ready to do this, as far as I can tell.